Stockscreener 앱 받기
3.855
0.75%
-0.145
전일 마감가:
$4.00
열려 있는:
$4.01
하루 거래량:
23,821
Relative Volume:
0.08
시가총액:
$187.09M
수익:
$114.70K
순이익/손실:
$-37.06M
주가수익비율:
-0.9655
EPS:
-3.9929
순현금흐름:
$-30.69M
1주 성능:
+5.59%
1개월 성능:
+22.53%
6개월 성능:
+133.53%
1년 성능:
+0.25%
1일 변동 폭
$3.8501
$4.015
1주일 범위
$3.5065
$4.04
52주 변동 폭
$1.00
$6.60
Sab Biotherapeutics Inc Stock (SABS) Company Profile
명칭
Sab Biotherapeutics Inc
전화
305-845-2813
주소
777 W 41ST ST, MIAMI BEACH
SABS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SABS
Sab Biotherapeutics Inc
|
3.93 | 190.43M | 114.70K | -37.06M | -30.69M | -3.9929 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.25 | 115.62B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
744.62 | 79.10B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
847.66 | 52.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.11 | 51.72B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
200.33 | 42.00B | 447.02M | -1.18B | -906.14M | -6.1812 |
Sab Biotherapeutics Inc Stock (SABS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-17 | 개시 | Leerink Partners | Outperform |
| 2025-05-14 | 재개 | H.C. Wainwright | Buy |
| 2024-10-09 | 개시 | Craig Hallum | Buy |
| 2024-08-28 | 개시 | Oppenheimer | Outperform |
| 2021-11-05 | 개시 | Chardan Capital Markets | Buy |
Sab Biotherapeutics Inc 주식(SABS)의 최신 뉴스
SAB BIO to Present Data Showcasing Progress in the Development of SAB-142 at the Asian Conference on Innovative Therapies for Diabetes Management - Investing News Network
SAB Biotherapeutics to Present Data on SAB-142 for Type 1 Diabetes at ATTD-Asia Conference 2025 - Quiver Quantitative
Institution Moves: Is Above Food Ingredients Inc. stock safe for conservative investorsNew Guidance & Technical Pattern Based Buy Signals - BỘ NỘI VỤ
Why analysts upgrade SAB Biotherapeutics Inc. Equity Warrant stockQuarterly Portfolio Review & Safe Swing Trade Setups - Newser
Will SAB Biotherapeutics Inc. Equity Warrant stock gain from lower inflationMarket Movers & Consistent Growth Equity Picks - Newser
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
How SAB Biotherapeutics Inc. stock performs in rate cut cyclesWeekly Profit Report & AI Forecast Swing Trade Picks - Newser
Will SAB Biotherapeutics Inc. Equity Warrant stock reach Wall Street targetsTrade Analysis Report & Daily Volume Surge Signals - Newser
Is SAB Biotherapeutics Inc. Equity Warrant stock a buy before product launchesEarnings Overview Report & Daily Technical Stock Forecast Reports - Newser
Weekly Recap: What margin trends mean for SAB Biotherapeutics Inc. stockMarket Performance Summary & Low Volatility Stock Recommendations - moha.gov.vn
How SAB Biotherapeutics Inc. Equity Warrant stock trades before earnings2025 EndofYear Setup & Short-Term High Return Strategies - BỘ NỘI VỤ
The growth track for SAB Biotherapeutics Inc (SABS) has changed recently - setenews.com
Will SAB Biotherapeutics Inc. stock benefit from green energy trendsEarnings Risk Summary & Accurate Entry/Exit Alerts - BỘ NỘI VỤ
Leerink Partnrs Has Optimistic View of SABS FY2025 Earnings - MarketBeat
Research Analysts Set Expectations for SABS FY2025 Earnings - Defense World
Q1 Earnings Forecast for SABS Issued By Leerink Partnrs - Defense World
SAB Biotherapeutics Inc Stock Analysis and ForecastEx-Dividend Date Alerts & Low Cost Stock Picks - earlytimes.in
SAB Biotherapeutics, Inc.'s (NASDAQ:SABS) biggest owners are individual investors who got richer after stock soared 22% last week - Yahoo Finance
SABS Q4 EPS Forecast Lifted by Brookline Capital Management - Defense World
SAB Biotherapeutics Inc. (SABS) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
What risks investors should watch in SAB Biotherapeutics Inc. stockQuarterly Trade Summary & AI Powered Market Entry Ideas - newser.com
Will SAB Biotherapeutics Inc. stock reach Wall Street targets2025 Valuation Update & Accurate Entry and Exit Point Alerts - newser.com
Trend analysis for SAB Biotherapeutics Inc. Equity Warrant this weekDollar Strength & AI Powered Market Entry Ideas - newser.com
Will SAB Biotherapeutics Inc. Equity Warrant stock outperform Dow Jones indexWeekly Volume Report & Growth Focused Investment Plans - newser.com
Is SAB Biotherapeutics Inc. forming a reversal patternJuly 2025 Big Picture & Accurate Intraday Trading Signals - newser.com
Why SAB Biotherapeutics Inc. stock remains a top recommendationBond Market & AI Based Buy/Sell Signal Reports - newser.com
Is SAB Biotherapeutics Inc. stock safe for conservative investors2025 Pullback Review & High Accuracy Trade Signal Alerts - newser.com
Using Bollinger Bands to evaluate SAB Biotherapeutics Inc. Equity WarrantRate Hike & Weekly Watchlist of Top Performers - newser.com
Is SAB Biotherapeutics Inc. Equity Warrant reversing from oversold territoryAnalyst Upgrade & Growth Oriented Trading Recommendations - newser.com
Will SAB Biotherapeutics Inc. stock deliver better than expected guidanceWeekly Investment Summary & Fast Exit and Entry Strategy Plans - newser.com
What risks investors should watch in SAB Biotherapeutics Inc. Equity Warrant stockPortfolio Update Report & Reliable Price Breakout Alerts - newser.com
SAB Biotherapeutics Reports Positive Q3 2025 Earnings - MSN
SAB Biotherapeutics, Inc. Warrant 2021-22.10.26 on SAB Biotherap - TradingView
What sentiment indicators say about SAB Biotherapeutics Inc. stock2025 Breakouts & Breakdowns & Smart Allocation Stock Tips - newser.com
Can SAB Biotherapeutics Inc. Equity Warrant stock resist sector downturns2025 Top Decliners & AI Based Buy and Sell Signals - newser.com
Ranking SAB Biotherapeutics Inc. Equity Warrant among high performing stocks via tools2025 Earnings Surprises & Verified Entry Point Signals - newser.com
Why SAB Biotherapeutics Inc. Equity Warrant stock is considered a top pickJuly 2025 Catalysts & Reliable Entry Point Trade Alerts - newser.com
Is SAB Biotherapeutics Inc. Equity Warrant a candidate for recovery playJuly 2025 Spike Watch & Real-Time Chart Breakout Alerts - newser.com
Chardan Capital Reiterates “Buy” Rating for SAB Biotherapeutics (NASDAQ:SABS) - Defense World
Sab Biotherapeutics Inc (SABS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Sab Biotherapeutics Inc 주식 (SABS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Sessa Capital (Master), L.P. | Director |
Sep 29 '25 |
Option Exercise |
1.75 |
1,740,000 |
3,045,000 |
2,198,457 |
0.42%
0.32%
자본화:
|
볼륨(24시간):